NCT00105157View on ClinicalTrials.gov

Safety and Efficacy of an Investigational Drug in Human Immunodeficiency Virus (HIV)-Infected Patients Failing Current Antiretroviral Therapies (0518-005)(COMPLETED)

PHASE2CompletedINTERVENTIONAL

Enrollment

179

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

October 31, 2006

Study Completion Date

July 31, 2009

Conditions

HIV InfectionsAcquired Immunodeficiency Syndrome

Interventions

DRUG

Comparator: MK0518

MK0518 oral tablets 200 mg b.i.d, for 24 weeks

DRUG

MK0518

MK0518 oral tablets 400 mg b.i.d, for 24 weeks

DRUG

MK0518

MK0518 oral tablets 600 mg b.i.d, for 24 weeks

DRUG

Placebo

Placebo to MK0518, oral tablet b.i.d, for 24 weeks

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00105157 - Safety and Efficacy of an Investigational Drug in Human Immunodeficiency Virus (HIV)-Infected Patients Failing Current Antiretroviral Therapies (0518-005)(COMPLETED) | Biotech Hunter | Biotech Hunter